RxDoctor Payments Data

Gilbert Leidig, MD

Cardiovascular Disease · Newark, DENPI 1902835770

Payments from drug & device makers

$1,463in general payments, 2019–2025

Across 73 payments — averaging $20.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$325
  • Novartis$257
  • Esperion Therapeutics, Inc.$146
  • Heartflow, Inc.$131
  • Akcea Therapeutics, Inc.$130
  • Johnson & Johnson$96
  • plus $379 from 14 others

What the payments were for

  • Food & beverage$1,43998%
  • Education$242%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,463 in reported general payments places this provider in the 40th percentile of 104 cardiovascular disease providers in Delaware.

See all cardiovascular disease providers in Delaware

Medicare billing

Part B allowed, 2024
$711,348
Medicare patients
3,302
Services billed
8,976

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban547$745,432
XareltoRivaroxaban446$573,089
EntrestoSacubitril/Valsartan81$128,841
Repatha SureclickEvolocumab82$93,121
BrilintaTicagrelor58$69,732
JardianceEmpagliflozin22$33,566
Atorvastatin Calcium1,315$21,057
MultaqDronedarone Hcl11$20,041
Praluent PenAlirocumab14$13,968
Metoprolol Succinate765$12,156
Ranolazine ErRanolazine94$11,423
Nebivolol Hcl116$10,504
Rosuvastatin Calcium438$10,108
Ezetimibe277$9,288
NexletolBempedoic Acid14$8,607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Lipitor$36$752,009563 claims
Johnson & JohnsonXarelto$96$573,089446 claims
NovartisEntresto$257$128,84181 claims
AstraZenecaBrilinta$13$69,73258 claims
Boehringer IngelheimJardiance, Pradaxa$12$36,18134 claims
Sanofi-aventis U.S. LLCMultaq$35$20,04111 claims
Esperion Therapeutics, Inc.Nexletol$146$8,60714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 104 cardiovascular disease providers in Delaware.

Other cardiovascular disease in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →